Hewlett Packard to pay $61 mil. for 14% stake in i-Stat.
This article was originally published in The Gray Sheet
Executive SummaryHEWLETT PACKARD'S $61 MIL. INVESTMENT IN i-STAT gives HP access to i-Stat's "thin-film" biosensor blood chemistry technology for integration into its OmniCare patient-monitoring system. The two companies announced on June 23 the signing of a strategic alliance -- under negotiation for nearly a year -- calling for HP to purchase 2.1 mil. preferred shares of i-Stat for $28.50 each. The deal will give HP a 14% fully-diluted stake in Princeton, New Jersey-based i-Stat.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.